vs

Side-by-side financial comparison of ESCALADE INC (ESCA) and PROCEPT BioRobotics Corp (PRCT). Click either name above to swap in a different company.

PROCEPT BioRobotics Corp is the larger business by last-quarter revenue ($83.1M vs $62.6M, roughly 1.3× ESCALADE INC). ESCALADE INC runs the higher net margin — 5.9% vs -38.1%, a 44.0% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs -2.2%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 4.5%).

Escalade Inc is a global sporting goods manufacturer and distributor that offers basketball systems, archery equipment, table tennis gear, game tables, and outdoor recreation accessories. It operates primarily across North America, Europe, and Asia Pacific, serving consumer retail, commercial fitness, and specialty sports segments.

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

ESCA vs PRCT — Head-to-Head

Bigger by revenue
PRCT
PRCT
1.3× larger
PRCT
$83.1M
$62.6M
ESCA
Growing faster (revenue YoY)
PRCT
PRCT
+22.4% gap
PRCT
20.2%
-2.2%
ESCA
Higher net margin
ESCA
ESCA
44.0% more per $
ESCA
5.9%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
4.5%
ESCA

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ESCA
ESCA
PRCT
PRCT
Revenue
$62.6M
$83.1M
Net Profit
$3.7M
$-31.6M
Gross Margin
27.7%
64.9%
Operating Margin
8.2%
-4.1%
Net Margin
5.9%
-38.1%
Revenue YoY
-2.2%
20.2%
Net Profit YoY
37.1%
-27.9%
EPS (diluted)
$0.27
$-0.56

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESCA
ESCA
PRCT
PRCT
Q1 26
$83.1M
Q4 25
$62.6M
$76.4M
Q3 25
$67.8M
$83.3M
Q2 25
$54.3M
$79.2M
Q1 25
$55.5M
$69.2M
Q4 24
$63.9M
$68.2M
Q3 24
$67.7M
$58.4M
Q2 24
$62.5M
$53.4M
Net Profit
ESCA
ESCA
PRCT
PRCT
Q1 26
$-31.6M
Q4 25
$3.7M
$-29.8M
Q3 25
$5.6M
$-21.4M
Q2 25
$1.8M
$-19.6M
Q1 25
$2.6M
$-24.7M
Q4 24
$2.7M
$-18.9M
Q3 24
$5.7M
$-21.0M
Q2 24
$2.8M
$-25.6M
Gross Margin
ESCA
ESCA
PRCT
PRCT
Q1 26
64.9%
Q4 25
27.7%
60.6%
Q3 25
28.1%
64.8%
Q2 25
24.7%
65.4%
Q1 25
26.7%
63.9%
Q4 24
24.9%
64.0%
Q3 24
24.8%
63.2%
Q2 24
24.2%
59.0%
Operating Margin
ESCA
ESCA
PRCT
PRCT
Q1 26
-4.1%
Q4 25
8.2%
-40.6%
Q3 25
10.8%
-27.8%
Q2 25
4.8%
-28.0%
Q1 25
6.6%
-39.7%
Q4 24
7.1%
-28.9%
Q3 24
11.8%
-38.4%
Q2 24
7.1%
-50.3%
Net Margin
ESCA
ESCA
PRCT
PRCT
Q1 26
-38.1%
Q4 25
5.9%
-39.1%
Q3 25
8.2%
-25.7%
Q2 25
3.4%
-24.7%
Q1 25
4.7%
-35.8%
Q4 24
4.2%
-27.6%
Q3 24
8.4%
-35.9%
Q2 24
4.5%
-48.0%
EPS (diluted)
ESCA
ESCA
PRCT
PRCT
Q1 26
$-0.56
Q4 25
$0.27
$-0.54
Q3 25
$0.40
$-0.38
Q2 25
$0.13
$-0.35
Q1 25
$0.19
$-0.45
Q4 24
$0.20
$-0.34
Q3 24
$0.40
$-0.40
Q2 24
$0.20
$-0.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESCA
ESCA
PRCT
PRCT
Cash + ST InvestmentsLiquidity on hand
$245.6M
Total DebtLower is stronger
$18.5M
$51.7M
Stockholders' EquityBook value
$173.2M
$347.7M
Total Assets
$222.1M
$487.1M
Debt / EquityLower = less leverage
0.11×
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESCA
ESCA
PRCT
PRCT
Q1 26
$245.6M
Q4 25
$286.5M
Q3 25
$294.3M
Q2 25
$302.7M
Q1 25
$316.2M
Q4 24
$333.7M
Q3 24
$196.8M
Q2 24
$214.1M
Total Debt
ESCA
ESCA
PRCT
PRCT
Q1 26
$51.7M
Q4 25
$18.5M
$51.6M
Q3 25
$51.6M
Q2 25
$51.5M
Q1 25
$51.5M
Q4 24
$25.6M
$51.5M
Q3 24
$51.4M
Q2 24
$51.4M
Stockholders' Equity
ESCA
ESCA
PRCT
PRCT
Q1 26
$347.7M
Q4 25
$173.2M
$365.9M
Q3 25
$172.3M
$380.3M
Q2 25
$168.3M
$385.8M
Q1 25
$168.8M
$389.2M
Q4 24
$169.0M
$402.2M
Q3 24
$170.1M
$241.2M
Q2 24
$166.0M
$251.8M
Total Assets
ESCA
ESCA
PRCT
PRCT
Q1 26
$487.1M
Q4 25
$222.1M
$508.1M
Q3 25
$232.5M
$511.5M
Q2 25
$218.3M
$513.1M
Q1 25
$222.1M
$519.4M
Q4 24
$226.3M
$534.0M
Q3 24
$244.9M
$374.1M
Q2 24
$243.1M
$374.4M
Debt / Equity
ESCA
ESCA
PRCT
PRCT
Q1 26
0.15×
Q4 25
0.11×
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.15×
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESCA
ESCA
PRCT
PRCT
Operating Cash FlowLast quarter
$14.9M
Free Cash FlowOCF − Capex
$13.7M
FCF MarginFCF / Revenue
21.8%
Capex IntensityCapex / Revenue
2.0%
Cash ConversionOCF / Net Profit
4.02×
TTM Free Cash FlowTrailing 4 quarters
$28.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESCA
ESCA
PRCT
PRCT
Q1 26
Q4 25
$14.9M
$-10.3M
Q3 25
$-965.0K
$-6.6M
Q2 25
$13.3M
$-15.0M
Q1 25
$3.8M
$-17.0M
Q4 24
$12.3M
$-32.4M
Q3 24
$10.5M
$-18.8M
Q2 24
$13.3M
$-15.7M
Free Cash Flow
ESCA
ESCA
PRCT
PRCT
Q1 26
Q4 25
$13.7M
$-12.2M
Q3 25
$-1.3M
$-9.5M
Q2 25
$12.9M
$-17.8M
Q1 25
$3.2M
$-18.8M
Q4 24
$11.7M
$-33.6M
Q3 24
$10.2M
$-19.0M
Q2 24
$12.5M
$-16.8M
FCF Margin
ESCA
ESCA
PRCT
PRCT
Q1 26
Q4 25
21.8%
-15.9%
Q3 25
-1.9%
-11.4%
Q2 25
23.7%
-22.5%
Q1 25
5.9%
-27.2%
Q4 24
18.4%
-49.2%
Q3 24
15.0%
-32.6%
Q2 24
20.0%
-31.4%
Capex Intensity
ESCA
ESCA
PRCT
PRCT
Q1 26
Q4 25
2.0%
2.4%
Q3 25
0.4%
3.4%
Q2 25
0.8%
3.5%
Q1 25
1.0%
2.7%
Q4 24
0.9%
1.7%
Q3 24
0.5%
0.4%
Q2 24
1.3%
2.0%
Cash Conversion
ESCA
ESCA
PRCT
PRCT
Q1 26
Q4 25
4.02×
Q3 25
-0.17×
Q2 25
7.28×
Q1 25
1.45×
Q4 24
4.55×
Q3 24
1.85×
Q2 24
4.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESCA
ESCA

Segment breakdown not available.

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

Related Comparisons